8-K: Atossa Therapeutics Announces $100 Million At-the-Market Offering

Atossa Therapeutics has entered into an agreement to sell up to $100 million of its common stock through an at-the-market offering.

Summary

• Atossa Therapeutics has entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $100 million of its common stock.
• The shares will be offered and sold through an at-the-market offering, which may include sales directly on the Nasdaq Capital Market.
• Atossa is not obligated to sell any shares and can suspend or terminate the agreement at any time.
• Jefferies will act as a sales agent and will use commercially reasonable efforts to sell the shares on Atossa's behalf.
• The company intends to use the proceeds for clinical development, working capital, and general corporate purposes, and may also use a portion for acquisitions or investments.
• Jefferies will receive a commission of up to 3.0% of the gross proceeds from the sales.
• The agreement can be terminated by either party with notice, or by Jefferies under certain circumstances, such as a material adverse change in Atossa's business.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the capital raise is necessary for the company's operations, it also introduces the risk of dilution for existing shareholders. The terms of the agreement are standard, and the company's intended use of proceeds is positive.

Positives

• The at-the-market offering provides Atossa with a flexible way to raise capital.
• The proceeds will support the clinical development of Atossa's product candidates.
• The company has the option to use proceeds for strategic acquisitions or investments.
• The agreement allows Atossa to suspend or terminate the offering at any time, providing flexibility.

Negatives

• The offering could dilute existing shareholders' ownership.
• The company will incur commission expenses of up to 3.0% of the gross proceeds.
• There is no guarantee that the company will be able to sell all of the shares.

Risks

• The company's ability to sell shares under the agreement is subject to market conditions.
• A material adverse change in the company's business or financial condition could impair the sales agent's ability to sell shares.
• The company may not be able to use the proceeds as effectively as planned.
• The offering could lead to a decrease in the company's stock price due to dilution.

Future Outlook

The company intends to use the proceeds from the offering for clinical development of its product candidates, working capital, general corporate purposes, and potentially for acquisitions or investments.

Industry Context

At-the-market offerings are a common method for biotech companies to raise capital, providing flexibility and access to funds as needed. This allows companies to take advantage of market conditions and fund ongoing operations and research.

Comparison to Industry Standards

• Many biotech companies, such as XOMA Corporation and Agenus Inc., have utilized at-the-market offerings to raise capital.
• The commission rate of 3.0% is within the typical range for such offerings.
• The intended use of proceeds for clinical development and working capital is standard for biotech companies in this stage of development.
• The size of the offering, $100 million, is significant and indicates a substantial need for capital to support the company's operations and growth.

Stakeholder Impact

• Shareholders may experience dilution of their ownership due to the issuance of new shares.
• Employees may benefit from the company's increased financial stability and ability to fund operations.
• Customers may benefit from the company's ability to continue developing its product candidates.
• Creditors may view the capital raise positively as it strengthens the company's financial position.

Next Steps

• Atossa will begin selling shares through Jefferies LLC as market conditions allow.
• The company will use the proceeds to fund clinical development, working capital, and general corporate purposes.
• Atossa may also explore potential acquisitions or investments using a portion of the proceeds.

Key Dates

Keywords

at-the-market offering, common stock, capital raise, Jefferies LLC, clinical development, working capital, dilution, securities, Nasdaq Capital Market